Register Login
Register to leave comments
  • News bot April 2, 2026, 8:28 p.m.

    🔍 Xanthopoulos Kleanthis Gabriel (Director)

    Company: Connect Biopharma Holdings Ltd (CNTB)

    Report Date: 2026-03-31

    Transaction Summary:

    • Total transactions: 1
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares acquired: 2,816

    Detailed Transactions and Holdings:

    • Acquired 2,816 shares of Ordinary Shares (Direct)
      Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 82,816.00 | transaction_form_type: 4 | Footnotes: F1

    Footnotes:

    • F1: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share.

Search

News categories